Keywords: UCB, Novartis, cardiovasculars, diabetes, Germany

UCB extends German cardio/diabetes deal with Novartis

Article | 29 August 2009

Print This

Belgium’s UCB and Swiss drug major Novartis have entered into a licensing agreement for cardiovascular and diabetes products in ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in